Clover Health Investments, Corp. filings document the company’s Medicare Advantage insurance business, physician enablement technology, operating results, governance, and material events. Recent 8-K reports furnish earnings releases, guidance updates, Medicare Advantage enrollment information, Regulation FD presentations, and supplemental shareholder Q&A materials related to financial performance and business priorities.
Proxy materials cover annual meeting matters, board and governance disclosures, executive compensation, equity awards, and related stockholder voting items. Other current reports document officer transitions, principal financial and accounting officer appointments, compensatory arrangements, and formal disclosures connected to the company’s remote-first corporate structure and public-company reporting obligations.
Andrew Toy, who serves as both a Director and the Chief Executive Officer of Clover Health Investments (CLOV), reported that on 08/08/2025 85,535 shares of Class A common stock were automatically withheld to satisfy tax obligations when 6.25% of time-based restricted stock units (RSUs) granted on 08/08/2022 vested. The form reports a per-share price of $2.18 for the transaction. After the withholding, Mr. Toy directly beneficially owns 10,474,512 shares. The remaining RSUs continue to vest quarterly in equal 6.25% installments, with a final vesting date of 08/08/2026, subject to his continued service.
Clover Health Investments, Corp. published written responses to a selection of shareholder questions submitted before its second-quarter 2025 earnings announcement to increase engagement with its investor base. The company furnished those responses as Exhibit 99.1, and the Co‑Founder and Executive Chairman, Vivek Garipalli, provided separate written responses furnished as Exhibit 99.2. Both exhibits are furnished with the Current Report and are also available on the company’s investor relations website. The company states these materials are furnished for disclosure purposes and are not "filed" for Section 18 purposes and are not incorporated by reference into other filings except by specific reference.
Vivek Garipalli, a director and 10% owner of Clover Health Investments (CLOV), reported purchases of Class A common stock on 08/07/2025 and 08/08/2025. He acquired 415,000 shares on 08/07/2025 at a weighted average price of $2.24 and 31,980 shares on 08/08/2025 at a weighted average price of $2.17, bringing his reported direct ownership to 1,856,247 Class A shares.
Table II discloses substantial Class B common stock that converts one-for-one into Class A: 6,904,343 Class A-equivalent shares held directly, plus 11,500,000 and 72,084,543 Class A-equivalent shares held indirectly by Caesar Clover, LLC and NJ Healthcare Investments, LLC, respectively. The filing states Garipalli serves as sole manager of those LLCs.
Clover Health (CLOV) Q2 2025 10-Q snapshot
Premiums climbed 34% YoY to $469.8 m, lifting total revenue to $477.6 m, yet net medical claims surged 52% to $378.0 m, pushing the medical loss ratio to ~80.5% (71% in Q2 2024). Operating loss was $10.6 m versus prior-year profit of $7.2 m; GAAP EPS fell to –$0.02.
First-half revenue rose 34% to $939.9 m while net loss narrowed to $11.9 m (–$0.02 EPS) from $16.0 m, aided by a $2.8 m favourable prior-year claims development. Stock-based compensation remained high at $52.6 m YTD.
Cash & equivalents ended at $188.6 m, down $5.9 m YTD. Operating cash flow swung to a $10.9 m outflow (vs. $79.7 m inflow last year); investing inflows of $44.5 m offset $39.5 m used for equity-related financing. Total assets were $575 m and equity improved to $344 m.
Unpaid claims declined 11% YTD to $139.7 m; investment portfolio posted a $1.8 m unrealised gain, turning OCI positive. Weighted-average diluted shares stood at 509 m.
Management continues to expand Clover Assistant and Counterpart Health SaaS but flags medical cost inflation, RADV audit exposure and regulatory uncertainty as key risks.